These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 30484333)

  • 21. Novel synthetic treatment options for migraine.
    Negro A; Martelletti P
    Expert Opin Pharmacother; 2021 May; 22(7):907-922. PubMed ID: 33369482
    [No Abstract]   [Full Text] [Related]  

  • 22. Emerging migraine treatments and drug targets.
    Olesen J; Ashina M
    Trends Pharmacol Sci; 2011 Jun; 32(6):352-9. PubMed ID: 21459461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What's New in the Treatment of Migraine?
    Digre KB
    J Neuroophthalmol; 2019 Sep; 39(3):352-359. PubMed ID: 31393282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors.
    Tajti J; Csáti A; Vécsei L
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1509-20. PubMed ID: 25253587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erenumab: First Global Approval.
    Markham A
    Drugs; 2018 Jul; 78(11):1157-1161. PubMed ID: 29968151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future targets for migraine treatment beyond CGRP.
    Al-Hassany L; Boucherie DM; Creeney H; van Drie RWA; Farham F; Favaretto S; Gollion C; Grangeon L; Lyons H; Marschollek K; Onan D; Pensato U; Stanyer E; Waliszewska-Prosół M; Wiels W; Chen HZ; Amin FM;
    J Headache Pain; 2023 Jun; 24(1):76. PubMed ID: 37370051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Migraine preventive treatment: monoclonal antibodies against calcitonine gene related peptide].
    Goicochea MT; Bonamico L
    Medicina (B Aires); 2021; 81(3):427-431. PubMed ID: 34137704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K; Michael RL; Rapoport AM
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gepants for the treatment of migraine.
    Negro A; Martelletti P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
    Schuster NM; Rapoport AM
    Clin Neuropharmacol; 2017; 40(4):169-174. PubMed ID: 28644160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Migraine overview and summary of current and emerging treatment options.
    Peters GL
    Am J Manag Care; 2019 Jan; 25(2 Suppl):S23-S34. PubMed ID: 30681821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eptinezumab for the treatment of migraine.
    Scuteri D; Corasaniti MT; Tonin P; Bagetta G
    Drugs Today (Barc); 2019 Nov; 55(11):695-703. PubMed ID: 31840684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Migraine treatment: the doors for the future are open, but with caution and prudence.
    Krymchantowski AV; Krymchantowski AGF; Jevoux CDC
    Arq Neuropsiquiatr; 2019 Feb; 77(2):115-121. PubMed ID: 30810596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review.
    Murray AM; Stern JI; Robertson CE; Chiang CC
    Curr Pain Headache Rep; 2022 Oct; 26(10):783-794. PubMed ID: 36063264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging experimental drugs in clinical trials for migraine: observations and key talking points.
    Wells-Gatnik WD; Wences Chirino TY; Onan FN; Onan D; Martelletti P
    Expert Opin Investig Drugs; 2023; 32(8):761-771. PubMed ID: 37672405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
    Ailani J; Burch RC; Robbins MS;
    Headache; 2021 Jul; 61(7):1021-1039. PubMed ID: 34160823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies for the prevention of migraine.
    Raffaelli B; Neeb L; Reuter U
    Expert Opin Biol Ther; 2019 Dec; 19(12):1307-1317. PubMed ID: 31550937
    [No Abstract]   [Full Text] [Related]  

  • 39. Targets for migraine treatment: beyond calcitonin gene-related peptide.
    Moreno-Ajona D; Villar-Martínez MD; Goadsby PJ
    Curr Opin Neurol; 2021 Jun; 34(3):363-372. PubMed ID: 33840777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.
    Urits I; Jones MR; Gress K; Charipova K; Fiocchi J; Kaye AD; Viswanath O
    Curr Pain Headache Rep; 2019 Mar; 23(5):29. PubMed ID: 30874961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.